表紙
市場調査レポート

帯状疱疹後神経痛:パイプライン分析

Postherpetic Neuralgia - Pipeline Review, H1 2016

発行 Global Markets Direct 商品コード 192785
出版日 ページ情報 英文 94 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.95円で換算しております。
Back to Top
帯状疱疹後神経痛:パイプライン分析 Postherpetic Neuralgia - Pipeline Review, H1 2016
出版日: 2016年04月13日 ページ情報: 英文 94 Pages
概要

帯状疱疹後神経痛は帯状疱疹(ヘルペス)の合併症で、水痘(帯状ヘルペス)ウイルスにより引き起こされます。主な徴候・症状として疼痛や、軽い接触・痒み・しびれにも敏感に感じる(アロディニア)、倦怠感、まひ状態などが挙げられます。疾病素質には年齢や、HIVウイルス・ホジキンリンパ腫への感染暦などが含まれています。主な治療薬には、抗けいれん薬や抗うつ剤、オピオイド鎮痛剤などがあります。

当レポートでは、世界各国での帯状疱疹後神経痛(PHN)治療用のパイプライン製品の開発状況について分析し、製品開発・上市の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などの情報をお届けします。

目次

イントロダクション

  • 分析範囲

帯状疱疹後神経痛の概要

治療薬の開発

  • 帯状疱疹後神経痛向けパイプライン製品:概要
  • 帯状疱疹後神経痛向けパイプライン製品:比較分析

各企業で開発中の帯状疱疹後神経痛治療薬

パイプライン製品の概略

  • 後期段階の製品
  • 治験段階の製品
  • 初期段階の製品
  • 不明確な段階にある製品

帯状疱疹後神経痛治療薬:開発中の製品の一覧(企業別)

帯状疱疹後神経痛治療薬の開発に従事している企業

  • Aestus Therapeutics, Inc.
  • Allergan Plc
  • アステラス製薬
  • Daewoong Pharmaceutical Co., Ltd.
  • 第一三共
  • Immune Pharmaceuticals Inc.
  • Merck & Co., Inc.
  • Nuvo Research Inc.
  • Pfizer Inc.
  • Phosphagenics Limited
  • Purdue Pharma L.P.
  • Relmada Therapeutics, Inc.
  • Scilex Pharmaceuticals, Inc.
  • Teva Pharmaceutical Industries Limited
  • Winston Pharmaceuticals, Inc.

帯状疱疹後神経痛:治療薬の評価

  • 単剤治療薬の場合
  • 併用治療薬の場合
  • 標的別
  • 作用機序別
  • 投与方法別
  • 分子の種類別

薬剤のプロファイル

  • (アミトリプチリン + 塩酸ケタミン)
    • 製品概要
    • 機能メカニズム
    • 研究開発(R&D)の進展状況
  • (塩酸ナルトレキソン + 塩酸クロニジン)
  • ASP-8477
  • ATX-08001
  • 塩酸ブピバカイン
  • C-746
  • CNV-2197944
  • DWP-05195
  • Flexicaine
  • funapide
  • FV-100
  • ケトプロフェン
  • 塩酸リドカイン
  • 塩酸リドカイン・パッチ
  • 塩酸メピバカイン
  • mirogabalin besylate
  • MK-8291
  • NXN-462
  • oxycodone ER
  • pregabalin CR
  • senrebotase
  • V-116517
  • ズカプサイシン

帯状疱疹後神経痛治療薬:パイプライン製品の最新動向

帯状疱疹後神経痛治療薬:開発が休止状態の製品

帯状疱疹後神経痛治療薬:開発が中止された製品

帯状疱疹後神経痛関連製品の開発のマイルストーン

  • 注目すべき最新動向・プレスリリース

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC7853IDB

Summary

Global Markets Direct's, 'Postherpetic Neuralgia - Pipeline Review, H1 2016', provides an overview of the Postherpetic Neuralgia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Postherpetic Neuralgia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Postherpetic Neuralgia and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Postherpetic Neuralgia
  • The report reviews pipeline therapeutics for Postherpetic Neuralgia by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Postherpetic Neuralgia therapeutics and enlists all their major and minor projects
  • The report assesses Postherpetic Neuralgia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Postherpetic Neuralgia

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Postherpetic Neuralgia
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Postherpetic Neuralgia pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Postherpetic Neuralgia Overview
  • Therapeutics Development
    • Pipeline Products for Postherpetic Neuralgia - Overview
  • Postherpetic Neuralgia - Therapeutics under Development by Companies
  • Postherpetic Neuralgia - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Postherpetic Neuralgia - Products under Development by Companies
  • Postherpetic Neuralgia - Companies Involved in Therapeutics Development
    • Aestus Therapeutics, Inc.
    • ContraVir Pharmaceuticals, Inc.
    • Daewoong Pharmaceutical Co., Ltd.
    • Daiichi Sankyo Company, Limited
    • Immune Pharmaceuticals Inc.
    • Kineta, Inc.
    • Merck & Co., Inc.
    • Pfizer Inc.
    • Phosphagenics Limited
    • Purdue Pharma L.P.
    • Relmada Therapeutics, Inc.
    • Scilex Pharmaceuticals, Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Toray Industries, Inc.
  • Postherpetic Neuralgia - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (amitriptyline + ketamine hydrochloride) - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • (clonidine hydrochloride + naltrexone hydrochloride) - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ATX-08001 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • bupivacaine hydrochloride - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • C-746 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CNV-2197944 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • DWP-05195 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Flexicaine Peel - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • funapide - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • FV-100 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ketoprofen - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • lidocaine hydrochloride - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • lidocaine hydrochloride patch - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • mepivacaine hydrochloride - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • mirogabalin besylate - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MK-8291 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • naltrexone hydrochloride - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NXN-462 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • pregabalin CR - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TRK-700 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • U-2902 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • V-116517 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • zucapsaicin - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Postherpetic Neuralgia - Recent Pipeline Updates
  • Postherpetic Neuralgia - Dormant Projects
  • Postherpetic Neuralgia - Discontinued Products
  • Postherpetic Neuralgia - Product Development Milestones
    • Featured News & Press Releases
      • Mar 03, 2016: ContraVir Pharmaceuticals Reports Positive Results Confirming the Safety of its Shingles Candidate FV-100 in a Drug-Drug Interaction Study
      • Dec 10, 2015: SCILEX Pharmaceuticals Announces Executive Hires
      • Sep 16, 2015: FDA Accepts SCILEX Pharmaceuticals' NDA Filing for ZTlido
      • Jun 09, 2015: ContraVir Pharmaceuticals Selects ImageIQ as Imaging CRO for Phase III Clinical Trial
      • Apr 02, 2015: Teva and Xenon Announce Enrollment of First Patient in a Phase 2b Study Evaluating TV-45070 for Postherpetic Neuralgia
      • Feb 20, 2015: ContraVir Pharmaceuticals Provides Clinical Update on FV-100
      • Feb 19, 2015: Xenon Pharmaceuticals Partner Teva to Initiate Phase 2b Clinical Trial of TV-45070 in Post-Herpetic Neuralgia
      • Feb 04, 2015: Daiichi Sankyo Announces First Patients in Large-scale, Multi-national Phase 3 Clinical Programs for Mirogabalin
      • Jan 07, 2015: ContraVir Pharmaceuticals Granted FDA Meeting to Discuss Proposal for Phase 3 Trial of FV-100
      • Dec 18, 2014: Pfizer Reports Top-Line Results From a Phase 3 Study Evaluating Pregabalin Controlled-Release Formulation as a Treatment for Patients With Postherpetic Neuralgia
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Postherpetic Neuralgia, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Comparative Analysis by Unknown Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Postherpetic Neuralgia - Pipeline by Aestus Therapeutics, Inc., H1 2016
  • Postherpetic Neuralgia - Pipeline by ContraVir Pharmaceuticals, Inc., H1 2016
  • Postherpetic Neuralgia - Pipeline by Daewoong Pharmaceutical Co., Ltd., H1 2016
  • Postherpetic Neuralgia - Pipeline by Daiichi Sankyo Company, Limited, H1 2016
  • Postherpetic Neuralgia - Pipeline by Immune Pharmaceuticals Inc., H1 2016
  • Postherpetic Neuralgia - Pipeline by Kineta, Inc., H1 2016
  • Postherpetic Neuralgia - Pipeline by Merck & Co., Inc., H1 2016
  • Postherpetic Neuralgia - Pipeline by Pfizer Inc., H1 2016
  • Postherpetic Neuralgia - Pipeline by Phosphagenics Limited, H1 2016
  • Postherpetic Neuralgia - Pipeline by Purdue Pharma L.P., H1 2016
  • Postherpetic Neuralgia - Pipeline by Relmada Therapeutics, Inc., H1 2016
  • Postherpetic Neuralgia - Pipeline by Scilex Pharmaceuticals, Inc., H1 2016
  • Postherpetic Neuralgia - Pipeline by Teva Pharmaceutical Industries Ltd., H1 2016
  • Postherpetic Neuralgia - Pipeline by Toray Industries, Inc., H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Assessment by Combination Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Postherpetic Neuralgia Therapeutics - Recent Pipeline Updates, H1 2016
  • Postherpetic Neuralgia - Dormant Projects, H1 2016
  • Postherpetic Neuralgia - Dormant Projects (Contd..1), H1 2016
  • Postherpetic Neuralgia - Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for Postherpetic Neuralgia, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Assessment by Combination Products, H1 2016
  • Number of Products by Top 10 Targets, H1 2016
  • Number of Products by Stage and Top 10 Targets, H1 2016
  • Number of Products by Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Types, H1 2016
Back to Top